多发性硬化症：用阿仑单抗重新编程多发性硬化症的免疫受体谱。
Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.
机构信息
Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48129 Münster, Germany.
出版信息
Nat Rev Neurol. 2013 Mar;9(3):125-6. doi: 10.1038/nrneurol.2013.2. Epub 2013 Jan 29.
PMID:23358486
Abstract
Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.
摘要
两项 III 期临床试验的结果表明，阿仑单抗——一种 T 细胞和 B 细胞耗竭抗体——在降低复发缓解型多发性硬化症的临床和临床前疾病活动指标方面具有疗效。这种免疫治疗药物的作用突出了 T 淋巴细胞在疾病早期发病机制中的相关性。
Zotero 插件